BioSpace News Archive

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its second quarter 2022 financial results on Thursday, August 11, 2022.

HealthTrackRx, the nation’s leading PCR diagnostic testing lab, is now offering a molecular test for detection of the human monkeypox virus.

OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. financial markets on Thursday, August 4, 2022.

Allakos Inc. (the “Company”) (Nasdaq: ALLK), today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors.

GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), announced that the company will release its financial results for the second quarter of fiscal year 2022 on August 15, 2022 after 4:00 p.m. (ET), followed by a conference call/live audio webcast to discuss the results at 5:00 p.m. (ET).

Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2022 financial results after market close on Wednesday, August 3, 2022.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended June 30, 2022 and provided an update on its product pipeline and corporate activities.

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it intends to offer and sell $250 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, in an underwritten public offering.

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the market.

Medpace Holdings, Inc. announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial Results Revenue for the three months ended June 30, 2022 increased 26.2% to $351.2 million, compared to $278.3 million for the comparable prior-year period.